LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth
Go back to LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth| Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) | Delayed: 7.48 -0.13 (1.71%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.61 | 52 Week High | $1.50 | |||
| Open | $7.58 | 52 Week Low | $0.08 | |||
| Day High | $7.76 | P/E | N/A | |||
| Day Low | $7.10 | EPS | $-0.05 | |||
| Volume | 511,254 | |||||
